Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | WM-S1-030 |
| Synonyms | |
| Therapy Description |
WM-S1-030 is a mutant receptor tyrosine kinase inhibitor, which potentially inhibits tumor growth (Cancer Res 2022;82(12_Suppl):Abstract nr 6219). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| WM-S1-030 | WMS1030|WM S1 030|WM-S1|WM S1 | WM-S1-030 is a mutant receptor tyrosine kinase inhibitor, which potentially inhibits tumor growth (Cancer Res 2022;82(12_Suppl):Abstract nr 6219). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT04801095 | Phase I | WM-S1-030 | A Phase I Study of WM-S1-030 in Patients With Advanced Solid Tumors | Unknown status | AUS | 1 |